vTv Therapeutics (VTVT) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 4:32pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: abnormal, accredited, acquisition, adaptive, alter, altered, Antidiabetic, assistance, Biological, Biopharma, blood, budget, calendar, claim, CODM, composition, comprised, Concurrently, Cowen, deducting, draft, durability, efficacy, embody, enhance, enhanced, exceeding, exemption, feature, fixed, float, flow, freestanding, frequency, glycated, hemoglobin, holder, Hong, hyperglycemia, input, intended, Kong, label, line, long, Macau, meaningful, mezzanine, Newsoara, percentage, permanent, person, phosphodiesterase, placement, posting, profile, protocol, randomized, reclassified, region, regularly, resigned, safety, secondary, segment, serum, statistically, symptomatic, Taiwan, TD, temporary, top, toxicity, traditional, transparency, twelve, unvested, urine

Removed: accelerated, acute, adjusted, aggregated, agonist, alternative, American, announced, appointed, appointee, appointing, arithmetic, assessed, Australia, BTD, calculated, Cantor, chair, chemistry, clarify, commercially, consecutive, consisted, contractual, contrast, delay, demonstrate, diabetic, directing, discretion, DKA, doubt, Dr, efficient, eligible, eliminate, eliminated, exceed, expedient, failure, fasting, fewer, final, Fitzgerald, forced, forward, Hangzhou, Huadong, hundred, hypoglycemic, idea, improved, insignificant, Isaacsohn, Jonathan, journal, June, ketone, Korea, leaving, lesser, Lincoln, liquidate, lose, lowest, LPC, maximum, measuring, mechanistic, Metabolism, MRCT, nominated, Obesity, observed, October, offered, OfferingSM, originally, oversee, Park, participate, pathway, percent, performed, Pharma, plasma, portion, practical, predecessor, President, protective, published, put, reallocated, reallocation, receptor, recoverability, reduced, Regular, removal, restriction, restructuring, sit, South, supplement, test, thereunder, traded, treated, unregistered, unwilling, week, withdrawal, worth, Zhongmei

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VTVT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Tuch, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2024


			By:			/s/ Steven Tuch
						Steven Tuch
						Chief Financial Officer